Hyderabad-Based Company Secures Five Country Patent for Its Neuro-Degenerative Drug

Suven Life Sciences has been granted patents for its drug used against neuro-degenerative diseases by Australia, China, Europe, South Korea and the US.

Suven Life Sciences has been granted patent for a drug used in the treatment of neuro-degenerative diseases by Australia, China, Europe, South Korea and the US. The patents are valid until 2031, 2030, 2031, 2030 and 2031, respectively.//

Suven Life CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally."

Mumbai-Based Drug Firm Gets USFDA Approval For Acne Treatment Medicine
Sun Pharma’s XiminoTM capsules are indicated for inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years and above.

The company has "secured patents in Australia, China, Europe, South Korea and USA to their new chemical entities for CNS therapy through mechanism of action H3 Inverse against."

With these new patents, Suven has a total of 22 granted patents from Australia, 19 from China, 17 from Europe, 17 from South Korea and 23 from the US.

"These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II," Suven said.

Increased USFDA Approvals for Indian Drug Firms Result in Better Sale of Drugs in the US
75 approvals were granted to Indian pharmaceutical companies between April and September 2015, compared with 72 in the year to March 2015.

Source-PTI

British Drug Firm Gets Approval For Long-Term Use of Its Blood Thinner Drug From USFDA
Patients with history of heart attack can now be treated with 60 mg of Brilinta twice daily along with a daily maintenance dose of aspirin beyond that first year.

Swiss Drug-maker Gets Breakthrough Therapy Designation From USFDA For Its Hemophilia Drug
Roche said ACE910 secured fast-track designation as they prepare separate Phase III trials, the first in patients with haemophilia A with factor VIII inhibitors.